EuroPharma refocuses on product development
devoting more attention to developing products and less to
distribution of its stalwart brands.
Products currently under development at the three-year-old company, which draws its inspiration from the European natural products marketplace, include a carb blocker, a safe and effective fat blocker, an anti-viral product, a herbal digestive, an Indian botanical said to improve muscle mass for athletes and convalescents and a blood sugar regulator.
It is also involved in a collaborative effort to bring a new immune modulator to market, and has obtained the exclusive US license to a patented anti-inflammatory product that is claimed be "the next generation in joint health".
"By partnering these and other products with highly reputable companies we can significantly impact the growth of the natural products industry," said Lemerond.
"We see an enormous opportunity to bring new life and energy to the new products arena - products that are based on science and meet the guidelines of the FDA and FTC."
In order to give these new products the attention they need to get off the ground, Lamerond has entered into an agreement with Enzymatic Therapy for licensing and distribution of its Renouvelle topical anti-aging skin care and SneezeEze allergy relief. It is expected that the partnership will be extended to other products in the future.
The partnership between EuroPharma and Enzymatic Therapy makes sense since both were founded by Lemerond - Enzymatic Therapy 25 years ago and EuroPharma just three years ago, following the merger of Enzymatic Therapy with Vitaline Formulas, NF Formulas and Tyler Formulas in 2000.
Over the decades, Lemerond takes credit for introducing several remedies to the US market, such as glucosamine sulfate, IP-6, menopause products and standardized herbal extracts.
